Valeant Pharmaceuticals has been in the spotlight for more than a year now for all the wrong reasons. After peaking at $264 a share in the summer of 2015, Valeant’s stock dipped below $20 at one point, with John and Jane Investor, along with some big-name money managers (see: Bill Ackman), feeling the pain.
Valeant’s two issues in a nutshell
At the heart of Valeant’s issues are its sudden lack of pricing power and its extraordinarily high debt levels.